trial · primary record
Spesolimab
Pyoderma Gangrenosum
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 90 |
| Primary completion | 2028-08-19 |
| Primary endpoint | Achievement of complete closure (PGAR-100 (100% pyoderma gangrenosum area reduction)) of the target PG ulcer at any time up to Week 26 and confirmed at the next consecutive visit (at least 2 weeks later) |
| Registry ID | NCT06624670 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:47.886Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06624670
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.